A Multi-center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab. for Patients With Hypertension and Dyslipidemia
Latest Information Update: 16 Jul 2024
Price :
$35 *
At a glance
- Drugs Amlodipine/olmesartan-medoxomil/rosuvastatin (Primary)
- Indications Dyslipidaemias; Hypertension
- Focus Therapeutic Use
- Sponsors Daewoong Pharmaceutical
- 01 Jul 2024 Primary and secondary outcome measures amended.
- 01 Jul 2024 Status changed from recruiting to completed.
- 08 Sep 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Sep 2021).